Dae Gon Ha
Stock Analyst at Stifel
(2.37)
# 2,427
Out of 5,182 analysts
55
Total ratings
35.56%
Success rate
4.52%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $98 → $125 | $92.48 | +35.16% | 6 | Feb 26, 2026 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.34 | +274.53% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.89 | +3.81% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $52.75 | +40.28% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.72 | -61.14% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.04 | +390.80% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $272.75 | -19.34% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $23.99 | +429.39% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.49 | +1,275.36% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.67 | +390.46% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $2.04 | +243.14% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.25 | +407.32% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $85.20 | -70.66% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.49 | +10.42% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $29.95 | +851.59% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.49 | +1,242.28% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.08 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $40.95 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.90 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.61 | +645.34% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $20.39 | +2,303.14% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $125
Current: $92.48
Upside: +35.16%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.34
Upside: +274.53%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.89
Upside: +3.81%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $52.75
Upside: +40.28%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.72
Upside: -61.14%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.04
Upside: +390.80%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $272.75
Upside: -19.34%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $23.99
Upside: +429.39%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.49
Upside: +1,275.36%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.67
Upside: +390.46%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $2.04
Upside: +243.14%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.25
Upside: +407.32%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $85.20
Upside: -70.66%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.49
Upside: +10.42%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $29.95
Upside: +851.59%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.08
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $40.95
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $8.90
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $20.39
Upside: +2,303.14%